Adaptive Biotechnologies (ADPT) EBITDA (2018 - 2026)

Adaptive Biotechnologies has disclosed EBITDA across 9 years of filings, most recently posting -$15.8 million for Q2 2026.

• In Q2 2026, EBITDA fell 159.85% year-over-year to -$15.8 million; the TTM figure through Jun 2026 stood at $35.5 million (up 213.5% YoY), while the FY2025 annual figure was $25.4 million, up 138.76% from the prior year.
• EBITDA came in at -$15.8 million for Q2 2026 at Adaptive Biotechnologies, down from $12.1 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of $30.7 million in Q3 2025 to a low of -$63.1 million in Q1 2022.
• Average EBITDA over 5 years is -$19.3 million, with a median of -$18.6 million recorded in 2024.
• Year-over-year, EBITDA jumped 595.85% in 2025 and tumbled 159.85% in 2026.
• Over 5 years, EBITDA stood at -$39.2 million in 2022, then jumped by 74.59% to -$10.0 million in 2023, then surged by 82.82% to -$1.7 million in 2024, then jumped by 595.85% to $8.5 million in 2025, then sank by 285.88% to -$15.8 million in 2026.
• Per Business Quant data, the three most recent EBITDA figures were -$15.8 million in Q2 2026, $12.1 million in Q1 2026, and $8.5 million in Q4 2025.